CelgeneRiskManagement.com
Login Page

Welcome to the Celgene REMS Program

To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products THALOMID® (thalidomide), REVLIMID® (lenalidomide) and POMALYST® (pomalidomide). The THALOMID REMS® program, REVLIMID REMS® program, and POMALYST REMS® program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.

If you would like to obtain more information about any of the Celgene REMS programs, please click on the program name below:

- **RevlimidREMS®**
  - Visit [www.REVLIMIDREMS.com](http://www.REVLIMIDREMS.com)
  - to learn more about the REVLIMID REMS® program.

- **PomalystREMS®**
  - Visit [www.POMALYSTREMS.com](http://www.POMALYSTREMS.com)
  - to learn more about the POMALYST REMS® program.

- **THALOMID REMS®**
  - Visit [www.THALOMIDREMS.com](http://www.THALOMIDREMS.com)
  - to learn more about the THALOMID REMS® program.

For prescribers, please enter your User Name and Password to manage your patients through a Celgene REMS program. If you do not have an online account, select Create User Account to establish an account. Patients currently enrolled in a Celgene REMS program are not required to create an online account to complete a survey. Please select Patient Surveys and enter the information requested to begin a survey.

To login to your account:

- User Name
- Password

Forgot Password?  » Login

Create User Account  Patient Surveys  Encuesta del paciente

Contact Us | Terms of Use | Privacy Policy
© 2005-2017, Celgene Corporation
**Welcome to the Celgene REMS Program**

To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products THALOMID® (thalidomide), REVLIMID® (lenalidomide) and POMALYST® (pomalidomide). The THALOMID REMS® program, REVLIMID REMS® program, and POMALYST REMS® program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.

If you would like to obtain more information about any of the Celgene REMS programs, please click on the program name below:

- **RevlimidREMS®**
  - Visit [www.REVIMIDREMS.com](http://www.REVIMIDREMS.com) to learn more about the REVLIMID REMS® program.

- **PomalystREMS®**
  - Visit [www.POMALYSTREMS.com](http://www.POMALYSTREMS.com) to learn more about the POMALYST REMS® program.

- **THALOMIDREMS®**
  - Visit [www.THALOMIDREMS.com](http://www.THALOMIDREMS.com) to learn more about the THALOMID REMS® program.

For prescribers, please enter your User Name and Password to manage your patients through a Celgene REMS program. If you do not have an online account, select Create User Account to establish an account. Patients currently enrolled in a Celgene REMS program are not required to create an online account to complete a survey. Please select Patient Surveys and enter the information requested to begin a survey.

To login to your account:

- **User Name**
- **Password**

[Login]
POMALYST REMS® module
About the POMALYST REMS® program

POMALYST® (pomalidomide), in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

To avoid embryo-fetal exposure, POMALYST is only available under a restricted distribution program called "POMALYST Risk Evaluation and Mitigation Strategy (REMS)." Only certified prescribers can prescribe POMALYST and only certified pharmacies can dispense POMALYST in the POMALYST REMS® program.

In order to receive POMALYST, all patients must be enrolled in the POMALYST REMS® program and agree to comply with the requirements of the POMALYST REMS® program.

Key points of the POMALYST REMS® program

For more information, please contact the Celgene Customer Care Center at 1-866-423-6435.

Download the Celgene REMS mobile app to your iPad by clicking here:

Privacy policy | Terms of Use | Site map | Contact us

This website is intended for residents of the United States only.

Reference ID: 4116984
Patient Resources

POMALYST® (pomalidomide) is indicated for patients who have received at least two prior therapies (including lenalidomide and a proteasome inhibitor) and have demonstrated disease progression on or within 60 days of completion of the last therapy.

What you need to know about the POMALYST REMS® program

Your doctor will enroll you in the POMALYST REMS® program so that you can receive your medication. Use the materials below to learn more about the POMALYST REMS® program and what you need to do.

- Patient Guide to POMALYST REMS® Program
- Patient Medication Guide
- Visit Planned Parenthood Site for Emergency Contraception Brochure
- Patient Survey Reminder Card
- Encuesta el paciente

You can take your mandatory confidential patient survey at CelgeneRiskManagement.com in English or Spanish by clicking one of the buttons below.

- Patient Survey
- Encuesta el paciente

You can also complete your survey by using the Celgene REMS mobile app for your iPad. Please download the app to your iPad by clicking here:

- Download the Celgene REMS mobile app for your iPad by clicking here:

Attention Females Who Can Get Pregnant

Unless you abstain from sexual intercourse with a male partner, you are required to use at least one highly effective birth control method and at least one additional effective method every time you take a dose of a medicine. Below, you will find a printable folder that you can bring with you to your next medical appointment that discusses your reproductive health. This will help you and your healthcare provider understand what types of birth control options are best for you.

- Birth Control Options to Discuss With Your Healthcare Provider

Privacy policy | Terms of Use | Site map | Contact us

POMALYST® and POMALYST REMS® are registered trademarks of Celgene Corporation.


This website is intended for residents of the United States only.